Trial Profile
An Open label Randomised, multicentre study to evaluate the efficacy of two Zometa (Zoledronic acid) schedules on bone mineral density in prostrate cancer patients undergoing Androgen deprivation Therapy (ADT).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jul 2020
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Male osteoporosis; Prostate cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 27 Jul 2020 Status changed from recruiting to completed.
- 17 May 2011 New trial record